But Pfizer's stock price recently bounced on its second-quarter earnings. Investors have been looking for a glimpse into Pfizer's future, and there is a lot to like as things begi ...

Robert F. Kennedy Jr., the health secretary and a longtime vaccine critic, announced in a statement Tuesday that $500 million ...

“Stratus,” originally known as Variant XFG, is the second most prominent strain of COVID in the United States. According to ...

So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel ...

These five large-cap value dividend stocks look poised to provide some second-half gains with steady ultra-high-yield ...

The federal government’s decision to slash $500 million in funding for mRNA vaccine research has sparked concern among health ...

Federal regulators are caught between old-guard conservatives who demand continued mRNA funding, Rep. Massie's demand to ...

An official overseeing implementation of the Make America Healthy Again agenda at the Department of Health and Human Services ...

Pima County health officials say fall vaccine supplies remain steady despite changes in federal research funding.

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...